Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of AZD2816 for prevention of COVID-19 caused by SARS-CoV-2 variants
2021-002530-17Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AstraZeneca. Primary endpoint: Primary endpoint (naïve unvaccinated cohort). Started Jun 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002530-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002530-17.